Skip to main
DTIL

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences is in a strong position with two highly differentiated gene editing programs in HBV and DMD, supported by robust data from the virtual NDR and EASL. With potential for a year-end 2026 PBGENE-HBV update at AASLD and first-patient dosing in PBGENE-DMD, investors look forward to 2026 key near-term inflections. While both programs come with high-risk/high-reward given limited near-term dataset size, the fundamentally differentiated mechanisms and promising dataset support a positive outlook for the company.

Bears say

Precision BioSciences is a clinical-stage gene editing company that utilizes its ARCUS platform to develop in vivo gene therapies for sophisticated gene edits. However, despite promising preclinical data for its PBGENE-DMD functional dystrophin gene restoration program, there are concerns about the limited addressable market and the high costs associated with gene therapy development. Additionally, the lack of a clear path to profitability and potential competition from other gene editing companies may pose risks to the company's financial performance.

Precision Biosciences (DTIL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Precision Biosciences (DTIL) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.